Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 3905 shares traded. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Price Performance
The company has a market cap of C$663,150.00, a price-to-earnings ratio of -0.50 and a beta of -0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The company has a fifty day moving average price of C$0.01 and a two-hundred day moving average price of C$0.02.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last posted its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.16 million for the quarter. As a group, equities research analysts anticipate that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current fiscal year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- Using the MarketBeat Stock Split Calculator
- Rocket Lab is the Right Stock for the Right Time
- Overbought Stocks Explained: Should You Trade Them?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- 3 Healthcare Dividend Stocks to Buy
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
